In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Roche partners discontinued inclacumab with Global Blood Therapeutics

Executive Summary

Global Blood Therapeutics Inc. (GBT) received exclusive worldwide rights, and sublicensing rights, to develop, manufacture, and commercialize Roche’s preclinical fully human monoclonal antibody inclacumab against P-selectin, a target in sickle cell disease. The deal also includes patent rights and know-how, as well as modified compounds derived from inclacumab and interacting with P-selectin. Concurrent with the present agreement, GBT licensed Roche nonexclusive global and royalty-free rights to inclacumab for diagnostics uses.
Deal Industry
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies